GSE13876: Survival-related profile, pathways, and transcription factors...
In bhklab/MetaGxOvarian: Transcriptomic Ovarian Cancer Datasets
Description
Format
Details
Value
Description
Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways.The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers.According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using approximately 35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.
Format
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
experimentData(eset):
Experiment data
Experimenter name: Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009 Feb 3; 6(2):e24.
Laboratory: Crijns, van der Zee 2009
Contact information:
Title: Survival-related profile, pathways, and transcription factors in ovarian cancer.
URL:
PMIDs: 19192944
Abstract: A 371 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Operon human v3 ~35K 70-mer two-color oligonucleotide microarrays
platform_shorttitle:
Operon v3 two-color
platform_summary:
OperonHumanV3
platform_manufacturer:
other
platform_distribution:
non-commercial
platform_accession:
GPL7759
version:
2015-09-22 19:11:43
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1 2 ... 37629 (20939 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
Details
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
assayData: 20939 features, 157 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
157.00 113.00 2.05 1.56 2.71
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
151 NA's
1 156
unique_patient_ID:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1 40 79 79 118 157
sample_type:
tumor
157
histological_type:
ser
157
primarysite:
ov
157
summarygrade:
high low NA's
85 59 13
summarystage:
late
157
grade:
1 2 3 4 NA's
14 45 82 3 13
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
21.00 50.00 60.00 57.95 67.00 84.00
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 360 630 1100 1470 7020
vital_status:
deceased living
113 44
uncurated_author_metadata:
title: Ovarian tumor sample 100 / Ovarian tumor sample 101///geo_accession: GSM405638 / GSM405874///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 41///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 197///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405638/GSM405638.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405874/GSM405874.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 103 / Ovarian tumor sample 104///geo_accession: GSM405608 / GSM405784///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 42///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 170///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405608/GSM405608.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405784/GSM405784.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 105 / Ovarian tumor sample 106///geo_accession: GSM405628 / GSM405629///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 43///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 402///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405628/GSM405628.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405629/GSM405629.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 108 / Ovarian tumor sample 109///geo_accession: GSM405700 / GSM405943///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 44///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 5///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405700/GSM405700.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405943/GSM405943.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 10 / Ovarian tumor sample 11///geo_accession: GSM405902 / GSM405903///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 24///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 459///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405902/GSM405902.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405903/GSM405903.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 111 / Ovarian tumor sample 112///geo_accession: GSM405598 / GSM405599///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 45///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 343///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405598/GSM405598.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405599/GSM405599.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 115 / Ovarian tumor sample 117///geo_accession: GSM405774 / GSM405776///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 46///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 56///characteristics_ch1.4: sample nr: 345///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405774/GSM405774.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405776/GSM405776.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 119 / Ovarian tumor sample 120///geo_accession: GSM405600 / GSM405805///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 47///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 379///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405600/GSM405600.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405805/GSM405805.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 122 / Ovarian tumor sample 123///geo_accession: GSM405651 / GSM405794///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 48///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 73///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 211///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405651/GSM405651.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405794/GSM405794.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 124 / Ovarian tumor sample 125///geo_accession: GSM405659 / GSM405787///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 49///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 346///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405659/GSM405659.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405787/GSM405787.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 126 / Ovarian tumor sample 127///geo_accession: GSM405614 / GSM405615///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 50///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 235///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405614/GSM405614.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405615/GSM405615.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 129 / Ovarian tumor sample 130///geo_accession: GSM405641 / GSM405887///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 1///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 200///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405641/GSM405641.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405887/GSM405887.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 131 / Ovarian tumor sample 132///geo_accession: GSM405597 / GSM405684///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 51///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 160///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405597/GSM405597.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405684/GSM405684.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 133 / Ovarian tumor sample 134///geo_accession: GSM405756 / GSM405914///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 52///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 234///characteristics_ch1.3: age: 26///characteristics_ch1.4: sample nr: 468///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405756/GSM405756.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405914/GSM405914.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 135 / Ovarian tumor sample 136///geo_accession: GSM405658 / GSM405753///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 53///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 66///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 219///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405658/GSM405658.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405753/GSM405753.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 137 / Ovarian tumor sample 138///geo_accession: GSM405568 / GSM405946///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 100///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 61///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405568/GSM405568.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405946/GSM405946.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 139 / Ovarian tumor sample 140///geo_accession: GSM405890 / GSM405937///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 101///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 42///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 450///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405890/GSM405890.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405937/GSM405937.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 13 / Ovarian tumor sample 14///geo_accession: GSM405578 / GSM405580///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 85///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 248///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405578/GSM405578.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405580/GSM405580.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 141 / Ovarian tumor sample 142///geo_accession: GSM405569 / GSM405601///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 102///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 132///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 117///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405569/GSM405569.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405601/GSM405601.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 145 / Ovarian tumor sample 146///geo_accession: GSM405817 / GSM405819///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 54///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 385///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405817/GSM405817.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405819/GSM405819.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 147 / Ovarian tumor sample 148///geo_accession: GSM405631 / GSM405904///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 55///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 190///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405631/GSM405631.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405904/GSM405904.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 149 / Ovarian tumor sample 150///geo_accession: GSM405716 / GSM405789///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 56///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 133///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 349///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405716/GSM405716.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405789/GSM405789.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 151///geo_accession: GSM405740///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 103///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 305///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405740/GSM405740.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 152 / Ovarian tumor sample 153///geo_accession: GSM405679 / GSM405822///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 57///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 392///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405679/GSM405679.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405822/GSM405822.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 155 / Ovarian tumor sample 156///geo_accession: GSM405769 / GSM405898///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 58///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 46///characteristics_ch1.4: sample nr: 455///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405769/GSM405769.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405898/GSM405898.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 157 / Ovarian tumor sample 158///geo_accession: GSM405701 / GSM405871///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 59///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 45///characteristics_ch1.4: sample nr: 263///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405701/GSM405701.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405871/GSM405871.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 159 / Ovarian tumor sample 160///geo_accession: GSM405722 / GSM405809///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 104///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 49///characteristics_ch1.3: age: 37///characteristics_ch1.4: sample nr: 283///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405722/GSM405722.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405809/GSM405809.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 161 / Ovarian tumor sample 162///geo_accession: GSM405826 / GSM405930///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 60///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 28///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 393///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405826/GSM405826.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405930/GSM405930.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 163 / Ovarian tumor sample 164///geo_accession: GSM405865 / GSM405916///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 105///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 471///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405865/GSM405865.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405916/GSM405916.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 165 / Ovarian tumor sample 166///geo_accession: GSM405634 / GSM405635///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 61///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 67///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 193///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405634/GSM405634.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405635/GSM405635.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 169 / Ovarian tumor sample 170///geo_accession: GSM405556 / GSM405695///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 62///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 258///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405556/GSM405556.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405695/GSM405695.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 171 / Ovarian tumor sample 172///geo_accession: GSM405559 / GSM405866///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 106///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 429///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405559/GSM405559.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405866/GSM405866.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 173 / Ovarian tumor sample 174///geo_accession: GSM405652 / GSM405959///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 63///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 213///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405652/GSM405652.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405959/GSM405959.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 176 / Ovarian tumor sample 177///geo_accession: GSM405746 / GSM405864///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 64///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 53///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 427///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405746/GSM405746.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405864/GSM405864.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 178 / Ovarian tumor sample 179///geo_accession: GSM405882 / GSM405913///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 107///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 119///characteristics_ch1.3: age: 21///characteristics_ch1.4: sample nr: 440///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405882/GSM405882.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405913/GSM405913.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 180 / Ovarian tumor sample 181///geo_accession: GSM405591 / GSM405654///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 65///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 70///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 214///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405591/GSM405591.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405654/GSM405654.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 185 / Ovarian tumor sample 186///geo_accession: GSM405613 / GSM405741///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 66///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 10///characteristics_ch1.3: age: 75///characteristics_ch1.4: sample nr: 179///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405613/GSM405613.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405741/GSM405741.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 187 / Ovarian tumor sample 188///geo_accession: GSM405791 / GSM405878///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 67///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 4///characteristics_ch1.3: age: 22///characteristics_ch1.4: sample nr: 352///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405791/GSM405791.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405878/GSM405878.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 189 / Ovarian tumor sample 190///geo_accession: GSM405626 / GSM405868///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 68///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 431///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405626/GSM405626.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405868/GSM405868.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 18 / Ovarian tumor sample 19///geo_accession: GSM405612 / GSM405642///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 86///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 177///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405612/GSM405612.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405642/GSM405642.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 191 / Ovarian tumor sample 192///geo_accession: GSM405566 / GSM405610///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 69///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 176///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405566/GSM405566.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405610/GSM405610.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 193 / Ovarian tumor sample 194///geo_accession: GSM405821 / GSM405823///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 70///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 395///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405821/GSM405821.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405823/GSM405823.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 196 / Ovarian tumor sample 197///geo_accession: GSM405603 / GSM405900///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 2///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 1///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 457///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405603/GSM405603.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405900/GSM405900.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 198 / Ovarian tumor sample 199///geo_accession: GSM405562 / GSM405852///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 3///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 413///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405562/GSM405562.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405852/GSM405852.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 1 / Ovarian tumor sample 2///geo_accession: GSM405750 / GSM405810///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 21///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 36///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 383///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405750/GSM405750.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405810/GSM405810.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 200 / Ovarian tumor sample 201///geo_accession: GSM405583 / GSM405593///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 71///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 133///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405583/GSM405583.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405593/GSM405593.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 202 / Ovarian tumor sample 203///geo_accession: GSM405637 / GSM405655///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 4///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 217///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405637/GSM405637.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405655/GSM405655.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 206 / Ovarian tumor sample 207///geo_accession: GSM405857 / GSM405901///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 5///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 40///characteristics_ch1.4: sample nr: 458///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405857/GSM405857.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405901/GSM405901.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 208 / Ovarian tumor sample 209///geo_accession: GSM405584 / GSM405661///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 72///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 223///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405584/GSM405584.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405661/GSM405661.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 210 / Ovarian tumor sample 211///geo_accession: GSM405757 / GSM405800///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 6///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 376///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405757/GSM405757.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405800/GSM405800.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 212 / Ovarian tumor sample 213///geo_accession: GSM405699 / GSM405935///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 7///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 262///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405699/GSM405699.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405935/GSM405935.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 214 / Ovarian tumor sample 215///geo_accession: GSM405713 / GSM405872///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 73///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 435///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405713/GSM405713.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405872/GSM405872.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 216 / Ovarian tumor sample 217///geo_accession: GSM405669 / GSM405754///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 8///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405669/GSM405669.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405754/GSM405754.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 21 / Ovarian tumor sample 22///geo_accession: GSM405625 / GSM405644///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 25///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 186///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405625/GSM405625.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405644/GSM405644.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 222 / Ovarian tumor sample 223///geo_accession: GSM405680 / GSM405856///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 108///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 419///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405680/GSM405680.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405856/GSM405856.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 224 / Ovarian tumor sample 225///geo_accession: GSM405742 / GSM405747///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 109///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 307///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405742/GSM405742.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405747/GSM405747.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 228 / Ovarian tumor sample 229///geo_accession: GSM405665 / GSM405832///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 74///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 396///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405665/GSM405665.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405832/GSM405832.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 230 / Ovarian tumor sample 231///geo_accession: GSM405570 / GSM405571///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 9///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 336///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405570/GSM405570.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405571/GSM405571.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 235 / Ovarian tumor sample 236///geo_accession: GSM405630 / GSM405668///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 10///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 80///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 232///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405630/GSM405630.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405668/GSM405668.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 237 / Ovarian tumor sample 238///geo_accession: GSM405807 / GSM405808///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 75///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 438///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405807/GSM405807.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405808/GSM405808.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 241 / Ovarian tumor sample 242///geo_accession: GSM405609 / GSM405928///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 11///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 173///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405609/GSM405609.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405928/GSM405928.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 244 / Ovarian tumor sample 245///geo_accession: GSM405624 / GSM405732///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 12///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 21///characteristics_ch1.3: age: 67///characteristics_ch1.4: sample nr: 185///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405624/GSM405624.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405732/GSM405732.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 246 / Ovarian tumor sample 247///geo_accession: GSM405686 / GSM405708///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 76///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 78///characteristics_ch1.4: sample nr: 272///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405686/GSM405686.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405708/GSM405708.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 248 / Ovarian tumor sample 249///geo_accession: GSM405724 / GSM405853///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 110///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 285///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405724/GSM405724.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405853/GSM405853.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 24 / Ovarian tumor sample 25///geo_accession: GSM405707 / GSM405954///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 87///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 67///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405707/GSM405707.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405954/GSM405954.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 250 / Ovarian tumor sample 251///geo_accession: GSM405899 / GSM405926///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 77///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 25///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405899/GSM405899.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405926/GSM405926.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 254 / Ovarian tumor sample 255///geo_accession: GSM405586 / GSM405633///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 78///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 59///characteristics_ch1.4: sample nr: 191///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405586/GSM405586.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405633/GSM405633.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 256 / Ovarian tumor sample 257///geo_accession: GSM405561 / GSM405621///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 111///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 111///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405561/GSM405561.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405621/GSM405621.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 258 / Ovarian tumor sample 259///geo_accession: GSM405696 / GSM405697///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 13///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 41///characteristics_ch1.4: sample nr: 259///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405696/GSM405696.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405697/GSM405697.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 261 / Ovarian tumor sample 262///geo_accession: GSM405678 / GSM405863///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 14///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 239///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405678/GSM405678.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405863/GSM405863.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 263 / Ovarian tumor sample 264///geo_accession: GSM405730 / GSM405798///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 15///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 6///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 371///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405730/GSM405730.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405798/GSM405798.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 265 / Ovarian tumor sample 266///geo_accession: GSM405606 / GSM405951///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 112///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 92///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 168///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405606/GSM405606.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405951/GSM405951.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 267 / Ovarian tumor sample 268///geo_accession: GSM405592 / GSM405703///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 113///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 266///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405592/GSM405592.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405703/GSM405703.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 269 / Ovarian tumor sample 270///geo_accession: GSM405619 / GSM405650///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 114///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 24///characteristics_ch1.3: age: 74///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405619/GSM405619.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405650/GSM405650.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 26 / Ovarian tumor sample 27///geo_accession: GSM405675 / GSM405758///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 26///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 61///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 329///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405675/GSM405675.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405758/GSM405758.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 273 / Ovarian tumor sample 274///geo_accession: GSM405579 / GSM405581///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 115///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 131///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405579/GSM405579.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405581/GSM405581.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 278 / Ovarian tumor sample 279///geo_accession: GSM405683 / GSM405879///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 79///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 39///characteristics_ch1.4: sample nr: 439///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405683/GSM405683.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405879/GSM405879.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 280 / Ovarian tumor sample 281///geo_accession: GSM405859 / GSM405917///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 116///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 117///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 472///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405859/GSM405859.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405917/GSM405917.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 282 / Ovarian tumor sample 283///geo_accession: GSM405611 / GSM405704///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 117///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 213///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 267///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405611/GSM405611.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405704/GSM405704.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 284 / Ovarian tumor sample 285///geo_accession: GSM405645 / GSM405647///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 118///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 43///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 202///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405645/GSM405645.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405647/GSM405647.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 289 / Ovarian tumor sample 290///geo_accession: GSM405620 / GSM405910///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 119///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 183///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405620/GSM405620.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405910/GSM405910.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 291 / Ovarian tumor sample 292///geo_accession: GSM405653 / GSM405799///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 120///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 374///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405653/GSM405653.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405799/GSM405799.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 293 / Ovarian tumor sample 294///geo_accession: GSM405770 / GSM405850///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 16///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 15///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 338///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405770/GSM405770.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405850/GSM405850.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 296 / Ovarian tumor sample 297///geo_accession: GSM405582 / GSM405692///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 121///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 253///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405582/GSM405582.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405692/GSM405692.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 298 / Ovarian tumor sample 299///geo_accession: GSM405860 / GSM405921///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 17///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 422///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405860/GSM405860.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405921/GSM405921.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 300 / Ovarian tumor sample 301///geo_accession: GSM405563 / GSM405869///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 122///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 50///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405563/GSM405563.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405869/GSM405869.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 304 / Ovarian tumor sample 305///geo_accession: GSM405567 / GSM405834///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 123///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 116///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405567/GSM405567.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405834/GSM405834.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 306 / Ovarian tumor sample 307///geo_accession: GSM405949 / GSM405960///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 124///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 7///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405949/GSM405949.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405960/GSM405960.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 309 / Ovarian tumor sample 310///geo_accession: GSM405605 / GSM405820///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 125///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 71///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 167///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405605/GSM405605.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405820/GSM405820.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 311 / Ovarian tumor sample 312///geo_accession: GSM405677 / GSM405687///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 126///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 249///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405677/GSM405677.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405687/GSM405687.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 313 / Ovarian tumor sample 314///geo_accession: GSM405714 / GSM405715///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 127///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 44///characteristics_ch1.4: sample nr: 280///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405714/GSM405714.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405715/GSM405715.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 316 / Ovarian tumor sample 317///geo_accession: GSM405772 / GSM405818///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 128///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 33///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405772/GSM405772.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405818/GSM405818.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 318 / Ovarian tumor sample 319///geo_accession: GSM405670 / GSM405811///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 80///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 50///characteristics_ch1.4: sample nr: 233///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405670/GSM405670.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405811/GSM405811.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 322 / Ovarian tumor sample 323///geo_accession: GSM405738 / GSM405883///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 129///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 130///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 441///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405738/GSM405738.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405883/GSM405883.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 324 / Ovarian tumor sample 325///geo_accession: GSM405739 / GSM405858///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 130///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 420///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405739/GSM405739.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405858/GSM405858.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 326 / Ovarian tumor sample 327///geo_accession: GSM405560 / GSM405737///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 131///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 109///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405560/GSM405560.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405737/GSM405737.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 328 / Ovarian tumor sample 329///geo_accession: GSM405693 / GSM405728///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 132///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 27///characteristics_ch1.4: sample nr: 292///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405693/GSM405693.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405728/GSM405728.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 32 / Ovarian tumor sample 33///geo_accession: GSM405694 / GSM405969///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 27///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 254///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405694/GSM405694.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405969/GSM405969.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 331 / Ovarian tumor sample 332///geo_accession: GSM405752 / GSM405892///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 133///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405752/GSM405752.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405892/GSM405892.xls.gz///data_row_count: 37632
1
(Other)
58
Value
An expression set
bhklab/MetaGxOvarian documentation built on Aug. 14, 2021, 1:59 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Description Format Details Value
Description
Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways.The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers.According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using approximately 35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.
Format
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 | experimentData(eset):
Experiment data
Experimenter name: Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009 Feb 3; 6(2):e24.
Laboratory: Crijns, van der Zee 2009
Contact information:
Title: Survival-related profile, pathways, and transcription factors in ovarian cancer.
URL:
PMIDs: 19192944
Abstract: A 371 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Operon human v3 ~35K 70-mer two-color oligonucleotide microarrays
platform_shorttitle:
Operon v3 two-color
platform_summary:
OperonHumanV3
platform_manufacturer:
other
platform_distribution:
non-commercial
platform_accession:
GPL7759
version:
2015-09-22 19:11:43
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: 1 2 ... 37629 (20939 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
|
Details
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 | assayData: 20939 features, 157 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
157.00 113.00 2.05 1.56 2.71
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
151 NA's
1 156
unique_patient_ID:
Min. 1st Qu. Median Mean 3rd Qu. Max.
1 40 79 79 118 157
sample_type:
tumor
157
histological_type:
ser
157
primarysite:
ov
157
summarygrade:
high low NA's
85 59 13
summarystage:
late
157
grade:
1 2 3 4 NA's
14 45 82 3 13
age_at_initial_pathologic_diagnosis:
Min. 1st Qu. Median Mean 3rd Qu. Max.
21.00 50.00 60.00 57.95 67.00 84.00
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 360 630 1100 1470 7020
vital_status:
deceased living
113 44
uncurated_author_metadata:
title: Ovarian tumor sample 100 / Ovarian tumor sample 101///geo_accession: GSM405638 / GSM405874///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 41///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 197///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405638/GSM405638.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405874/GSM405874.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 103 / Ovarian tumor sample 104///geo_accession: GSM405608 / GSM405784///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 42///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 170///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405608/GSM405608.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405784/GSM405784.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 105 / Ovarian tumor sample 106///geo_accession: GSM405628 / GSM405629///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 43///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 402///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405628/GSM405628.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405629/GSM405629.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 108 / Ovarian tumor sample 109///geo_accession: GSM405700 / GSM405943///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 44///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 5///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405700/GSM405700.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405943/GSM405943.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 10 / Ovarian tumor sample 11///geo_accession: GSM405902 / GSM405903///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 24///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 459///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405902/GSM405902.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405903/GSM405903.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 111 / Ovarian tumor sample 112///geo_accession: GSM405598 / GSM405599///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 45///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 343///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405598/GSM405598.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405599/GSM405599.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 115 / Ovarian tumor sample 117///geo_accession: GSM405774 / GSM405776///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 46///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 56///characteristics_ch1.4: sample nr: 345///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405774/GSM405774.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405776/GSM405776.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 119 / Ovarian tumor sample 120///geo_accession: GSM405600 / GSM405805///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 47///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 379///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405600/GSM405600.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405805/GSM405805.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 122 / Ovarian tumor sample 123///geo_accession: GSM405651 / GSM405794///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 48///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 73///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 211///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405651/GSM405651.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405794/GSM405794.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 124 / Ovarian tumor sample 125///geo_accession: GSM405659 / GSM405787///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 49///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 346///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405659/GSM405659.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405787/GSM405787.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 126 / Ovarian tumor sample 127///geo_accession: GSM405614 / GSM405615///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 50///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 235///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405614/GSM405614.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405615/GSM405615.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 129 / Ovarian tumor sample 130///geo_accession: GSM405641 / GSM405887///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 1///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 200///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405641/GSM405641.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405887/GSM405887.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 131 / Ovarian tumor sample 132///geo_accession: GSM405597 / GSM405684///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 51///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 160///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405597/GSM405597.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405684/GSM405684.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 133 / Ovarian tumor sample 134///geo_accession: GSM405756 / GSM405914///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 52///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 234///characteristics_ch1.3: age: 26///characteristics_ch1.4: sample nr: 468///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405756/GSM405756.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405914/GSM405914.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 135 / Ovarian tumor sample 136///geo_accession: GSM405658 / GSM405753///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 53///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 66///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 219///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405658/GSM405658.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405753/GSM405753.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 137 / Ovarian tumor sample 138///geo_accession: GSM405568 / GSM405946///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 100///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 61///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405568/GSM405568.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405946/GSM405946.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 139 / Ovarian tumor sample 140///geo_accession: GSM405890 / GSM405937///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 101///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 42///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 450///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405890/GSM405890.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405937/GSM405937.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 13 / Ovarian tumor sample 14///geo_accession: GSM405578 / GSM405580///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 85///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 25///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 248///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405578/GSM405578.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405580/GSM405580.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 141 / Ovarian tumor sample 142///geo_accession: GSM405569 / GSM405601///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 102///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 132///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 117///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405569/GSM405569.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405601/GSM405601.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 145 / Ovarian tumor sample 146///geo_accession: GSM405817 / GSM405819///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 54///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 385///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405817/GSM405817.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405819/GSM405819.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 147 / Ovarian tumor sample 148///geo_accession: GSM405631 / GSM405904///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 55///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 190///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405631/GSM405631.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405904/GSM405904.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 149 / Ovarian tumor sample 150///geo_accession: GSM405716 / GSM405789///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 56///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 133///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 349///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405716/GSM405716.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405789/GSM405789.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 151///geo_accession: GSM405740///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 103///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 305///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405740/GSM405740.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 152 / Ovarian tumor sample 153///geo_accession: GSM405679 / GSM405822///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 57///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 20///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 392///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405679/GSM405679.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405822/GSM405822.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 155 / Ovarian tumor sample 156///geo_accession: GSM405769 / GSM405898///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 58///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 46///characteristics_ch1.4: sample nr: 455///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405769/GSM405769.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405898/GSM405898.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 157 / Ovarian tumor sample 158///geo_accession: GSM405701 / GSM405871///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 59///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 45///characteristics_ch1.4: sample nr: 263///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405701/GSM405701.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405871/GSM405871.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 159 / Ovarian tumor sample 160///geo_accession: GSM405722 / GSM405809///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 104///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 49///characteristics_ch1.3: age: 37///characteristics_ch1.4: sample nr: 283///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405722/GSM405722.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405809/GSM405809.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 161 / Ovarian tumor sample 162///geo_accession: GSM405826 / GSM405930///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 60///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 28///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 393///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405826/GSM405826.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405930/GSM405930.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 163 / Ovarian tumor sample 164///geo_accession: GSM405865 / GSM405916///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 105///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 471///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405865/GSM405865.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405916/GSM405916.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 165 / Ovarian tumor sample 166///geo_accession: GSM405634 / GSM405635///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 61///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 67///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 193///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405634/GSM405634.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405635/GSM405635.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 169 / Ovarian tumor sample 170///geo_accession: GSM405556 / GSM405695///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 62///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 258///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405556/GSM405556.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405695/GSM405695.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 171 / Ovarian tumor sample 172///geo_accession: GSM405559 / GSM405866///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 106///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 49///characteristics_ch1.4: sample nr: 429///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405559/GSM405559.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405866/GSM405866.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 173 / Ovarian tumor sample 174///geo_accession: GSM405652 / GSM405959///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 63///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 213///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405652/GSM405652.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405959/GSM405959.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 176 / Ovarian tumor sample 177///geo_accession: GSM405746 / GSM405864///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 64///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 53///characteristics_ch1.3: age: 63///characteristics_ch1.4: sample nr: 427///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405746/GSM405746.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405864/GSM405864.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 178 / Ovarian tumor sample 179///geo_accession: GSM405882 / GSM405913///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 107///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 119///characteristics_ch1.3: age: 21///characteristics_ch1.4: sample nr: 440///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405882/GSM405882.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405913/GSM405913.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 180 / Ovarian tumor sample 181///geo_accession: GSM405591 / GSM405654///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 65///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 70///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 214///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405591/GSM405591.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405654/GSM405654.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 185 / Ovarian tumor sample 186///geo_accession: GSM405613 / GSM405741///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 66///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 10///characteristics_ch1.3: age: 75///characteristics_ch1.4: sample nr: 179///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405613/GSM405613.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405741/GSM405741.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 187 / Ovarian tumor sample 188///geo_accession: GSM405791 / GSM405878///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 67///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 4///characteristics_ch1.3: age: 22///characteristics_ch1.4: sample nr: 352///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405791/GSM405791.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405878/GSM405878.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 189 / Ovarian tumor sample 190///geo_accession: GSM405626 / GSM405868///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 68///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 30///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 431///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405626/GSM405626.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405868/GSM405868.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 18 / Ovarian tumor sample 19///geo_accession: GSM405612 / GSM405642///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 86///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 177///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405612/GSM405612.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405642/GSM405642.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 191 / Ovarian tumor sample 192///geo_accession: GSM405566 / GSM405610///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 69///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 8///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 176///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405566/GSM405566.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405610/GSM405610.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 193 / Ovarian tumor sample 194///geo_accession: GSM405821 / GSM405823///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 70///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 395///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405821/GSM405821.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405823/GSM405823.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 196 / Ovarian tumor sample 197///geo_accession: GSM405603 / GSM405900///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 2///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 1///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 457///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405603/GSM405603.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405900/GSM405900.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 198 / Ovarian tumor sample 199///geo_accession: GSM405562 / GSM405852///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 3///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 413///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405562/GSM405562.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405852/GSM405852.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 1 / Ovarian tumor sample 2///geo_accession: GSM405750 / GSM405810///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 21///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 36///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 383///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405750/GSM405750.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405810/GSM405810.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 200 / Ovarian tumor sample 201///geo_accession: GSM405583 / GSM405593///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 71///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 133///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405583/GSM405583.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405593/GSM405593.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 202 / Ovarian tumor sample 203///geo_accession: GSM405637 / GSM405655///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 4///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 217///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405637/GSM405637.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405655/GSM405655.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 206 / Ovarian tumor sample 207///geo_accession: GSM405857 / GSM405901///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 5///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 7///characteristics_ch1.3: age: 40///characteristics_ch1.4: sample nr: 458///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405857/GSM405857.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405901/GSM405901.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 208 / Ovarian tumor sample 209///geo_accession: GSM405584 / GSM405661///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 72///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 223///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405584/GSM405584.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405661/GSM405661.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 210 / Ovarian tumor sample 211///geo_accession: GSM405757 / GSM405800///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 6///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 64///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 376///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405757/GSM405757.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405800/GSM405800.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 212 / Ovarian tumor sample 213///geo_accession: GSM405699 / GSM405935///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 7///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 17///characteristics_ch1.3: age: 72///characteristics_ch1.4: sample nr: 262///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405699/GSM405699.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405935/GSM405935.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 214 / Ovarian tumor sample 215///geo_accession: GSM405713 / GSM405872///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 73///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 65///characteristics_ch1.4: sample nr: 435///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405713/GSM405713.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405872/GSM405872.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 216 / Ovarian tumor sample 217///geo_accession: GSM405669 / GSM405754///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 8///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405669/GSM405669.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405754/GSM405754.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 21 / Ovarian tumor sample 22///geo_accession: GSM405625 / GSM405644///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 25///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 186///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405625/GSM405625.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405644/GSM405644.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 222 / Ovarian tumor sample 223///geo_accession: GSM405680 / GSM405856///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 108///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 419///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405680/GSM405680.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405856/GSM405856.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 224 / Ovarian tumor sample 225///geo_accession: GSM405742 / GSM405747///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 109///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr: 307///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405742/GSM405742.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405747/GSM405747.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 228 / Ovarian tumor sample 229///geo_accession: GSM405665 / GSM405832///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 74///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 64///characteristics_ch1.4: sample nr: 396///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405665/GSM405665.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405832/GSM405832.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 230 / Ovarian tumor sample 231///geo_accession: GSM405570 / GSM405571///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 9///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 18///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 336///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405570/GSM405570.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405571/GSM405571.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 235 / Ovarian tumor sample 236///geo_accession: GSM405630 / GSM405668///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 10///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 80///characteristics_ch1.3: age: 54///characteristics_ch1.4: sample nr: 232///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405630/GSM405630.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405668/GSM405668.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 237 / Ovarian tumor sample 238///geo_accession: GSM405807 / GSM405808///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 75///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 13///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 438///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405807/GSM405807.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405808/GSM405808.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 241 / Ovarian tumor sample 242///geo_accession: GSM405609 / GSM405928///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 11///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 5///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 173///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405609/GSM405609.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405928/GSM405928.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 244 / Ovarian tumor sample 245///geo_accession: GSM405624 / GSM405732///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 12///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 21///characteristics_ch1.3: age: 67///characteristics_ch1.4: sample nr: 185///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405624/GSM405624.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405732/GSM405732.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 246 / Ovarian tumor sample 247///geo_accession: GSM405686 / GSM405708///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 76///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 78///characteristics_ch1.4: sample nr: 272///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405686/GSM405686.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405708/GSM405708.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 248 / Ovarian tumor sample 249///geo_accession: GSM405724 / GSM405853///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 110///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 41///characteristics_ch1.3: age: 73///characteristics_ch1.4: sample nr: 285///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405724/GSM405724.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405853/GSM405853.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 24 / Ovarian tumor sample 25///geo_accession: GSM405707 / GSM405954///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 87///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 67///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405707/GSM405707.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405954/GSM405954.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 250 / Ovarian tumor sample 251///geo_accession: GSM405899 / GSM405926///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 77///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 11///characteristics_ch1.3: age: 25///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405899/GSM405899.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405926/GSM405926.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 254 / Ovarian tumor sample 255///geo_accession: GSM405586 / GSM405633///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 78///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 59///characteristics_ch1.4: sample nr: 191///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405586/GSM405586.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405633/GSM405633.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 256 / Ovarian tumor sample 257///geo_accession: GSM405561 / GSM405621///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 111///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr: 111///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405561/GSM405561.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405621/GSM405621.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 258 / Ovarian tumor sample 259///geo_accession: GSM405696 / GSM405697///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 13///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 41///characteristics_ch1.4: sample nr: 259///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405696/GSM405696.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405697/GSM405697.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 261 / Ovarian tumor sample 262///geo_accession: GSM405678 / GSM405863///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 14///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 239///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405678/GSM405678.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405863/GSM405863.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 263 / Ovarian tumor sample 264///geo_accession: GSM405730 / GSM405798///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 15///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 6///characteristics_ch1.3: age: 68///characteristics_ch1.4: sample nr: 371///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405730/GSM405730.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405798/GSM405798.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 265 / Ovarian tumor sample 266///geo_accession: GSM405606 / GSM405951///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 112///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 92///characteristics_ch1.3: age: 51///characteristics_ch1.4: sample nr: 168///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405606/GSM405606.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405951/GSM405951.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 267 / Ovarian tumor sample 268///geo_accession: GSM405592 / GSM405703///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 113///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 31///characteristics_ch1.3: age: 62///characteristics_ch1.4: sample nr: 266///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405592/GSM405592.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405703/GSM405703.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 269 / Ovarian tumor sample 270///geo_accession: GSM405619 / GSM405650///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 114///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 24///characteristics_ch1.3: age: 74///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405619/GSM405619.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405650/GSM405650.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 26 / Ovarian tumor sample 27///geo_accession: GSM405675 / GSM405758///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 26///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 61///characteristics_ch1.3: age: 71///characteristics_ch1.4: sample nr: 329///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405675/GSM405675.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405758/GSM405758.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 273 / Ovarian tumor sample 274///geo_accession: GSM405579 / GSM405581///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 115///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 14///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 131///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405579/GSM405579.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405581/GSM405581.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 278 / Ovarian tumor sample 279///geo_accession: GSM405683 / GSM405879///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 79///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 39///characteristics_ch1.4: sample nr: 439///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405683/GSM405683.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405879/GSM405879.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 280 / Ovarian tumor sample 281///geo_accession: GSM405859 / GSM405917///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 116///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 117///characteristics_ch1.3: age: 52///characteristics_ch1.4: sample nr: 472///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405859/GSM405859.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405917/GSM405917.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 282 / Ovarian tumor sample 283///geo_accession: GSM405611 / GSM405704///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 117///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 213///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 267///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405611/GSM405611.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405704/GSM405704.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 284 / Ovarian tumor sample 285///geo_accession: GSM405645 / GSM405647///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 118///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 43///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 202///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405645/GSM405645.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405647/GSM405647.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 289 / Ovarian tumor sample 290///geo_accession: GSM405620 / GSM405910///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 119///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 12///characteristics_ch1.3: age: 57///characteristics_ch1.4: sample nr: 183///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405620/GSM405620.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405910/GSM405910.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 291 / Ovarian tumor sample 292///geo_accession: GSM405653 / GSM405799///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 120///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 374///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405653/GSM405653.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405799/GSM405799.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 293 / Ovarian tumor sample 294///geo_accession: GSM405770 / GSM405850///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 16///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 15///characteristics_ch1.3: age: 55///characteristics_ch1.4: sample nr: 338///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405770/GSM405770.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405850/GSM405850.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 296 / Ovarian tumor sample 297///geo_accession: GSM405582 / GSM405692///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 121///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 253///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405582/GSM405582.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405692/GSM405692.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 298 / Ovarian tumor sample 299///geo_accession: GSM405860 / GSM405921///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 17///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 2///characteristics_ch1.3: age: 70///characteristics_ch1.4: sample nr: 422///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405860/GSM405860.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405921/GSM405921.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 300 / Ovarian tumor sample 301///geo_accession: GSM405563 / GSM405869///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 122///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 50///characteristics_ch1.3: age: 53///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405563/GSM405563.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405869/GSM405869.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 304 / Ovarian tumor sample 305///geo_accession: GSM405567 / GSM405834///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 123///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 59///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 116///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405567/GSM405567.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405834/GSM405834.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 306 / Ovarian tumor sample 307///geo_accession: GSM405949 / GSM405960///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 124///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 19///characteristics_ch1.3: age: 48///characteristics_ch1.4: sample nr: 7///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405949/GSM405949.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405960/GSM405960.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 309 / Ovarian tumor sample 310///geo_accession: GSM405605 / GSM405820///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 125///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 71///characteristics_ch1.3: age: 66///characteristics_ch1.4: sample nr: 167///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405605/GSM405605.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405820/GSM405820.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 311 / Ovarian tumor sample 312///geo_accession: GSM405677 / GSM405687///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 126///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 249///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405677/GSM405677.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405687/GSM405687.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 313 / Ovarian tumor sample 314///geo_accession: GSM405714 / GSM405715///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 127///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 37///characteristics_ch1.3: age: 44///characteristics_ch1.4: sample nr: 280///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics: STATUS: 0 = end of follow-up or death unrelated to ovarian cancer ; 1 = death due to ovarian cancer FUMND: Months from primary surgery SAMPLE NR: Unique RNA reference number///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405714/GSM405714.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405715/GSM405715.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 316 / Ovarian tumor sample 317///geo_accession: GSM405772 / GSM405818///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 128///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 9///characteristics_ch1.3: age: 42///characteristics_ch1.4: sample nr: 33///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405772/GSM405772.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405818/GSM405818.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 318 / Ovarian tumor sample 319///geo_accession: GSM405670 / GSM405811///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 80///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 47///characteristics_ch1.3: age: 50///characteristics_ch1.4: sample nr: 233///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405670/GSM405670.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405811/GSM405811.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 322 / Ovarian tumor sample 323///geo_accession: GSM405738 / GSM405883///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 129///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 130///characteristics_ch1.3: age: 69///characteristics_ch1.4: sample nr: 441///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405738/GSM405738.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405883/GSM405883.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 324 / Ovarian tumor sample 325///geo_accession: GSM405739 / GSM405858///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 130///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 60///characteristics_ch1.4: sample nr: 420///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405739/GSM405739.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405858/GSM405858.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 326 / Ovarian tumor sample 327///geo_accession: GSM405560 / GSM405737///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 131///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 33///characteristics_ch1.3: age: 58///characteristics_ch1.4: sample nr: 109///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405560/GSM405560.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405737/GSM405737.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 328 / Ovarian tumor sample 329///geo_accession: GSM405693 / GSM405728///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 132///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 16///characteristics_ch1.3: age: 27///characteristics_ch1.4: sample nr: 292///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405693/GSM405693.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405728/GSM405728.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 32 / Ovarian tumor sample 33///geo_accession: GSM405694 / GSM405969///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 27///characteristics_ch1.1: status: 0///characteristics_ch1.2: fumnd: 29///characteristics_ch1.3: age: 43///characteristics_ch1.4: sample nr: 254///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy3 / Cy5///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 2 in raw data file ; Characteristics / Channel 1 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405694/GSM405694.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405969/GSM405969.xls.gz///data_row_count: 37632
1
title: Ovarian tumor sample 331 / Ovarian tumor sample 332///geo_accession: GSM405752 / GSM405892///status: Public on May 20 2009///submission_date: May 19 2009///last_update_date: May 20 2009///type: RNA///channel_count: 1///source_name_ch1: Advanced stage serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: assigned unique patient id: 133///characteristics_ch1.1: status: 1///characteristics_ch1.2: fumnd: 22///characteristics_ch1.3: age: 61///characteristics_ch1.4: sample nr / sample nr///treatment_protocol_ch1: All tumor samples were obtained at primary surgery prior to chemotherapy.///growth_protocol_ch1: All tumor samples were flash frozen in liquid nitrogen and stored at -80 C.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA from tumor samples was pelleted through cesium chloride density gradient ultracentrifugation (Roche, Almere, the Netherlands). After total RNA samples had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they were checked for residual DNA using a dinucleotide primer set D11S875 specific for genomic DNA. mRNA was linearly amplified by in vitro transcription using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) [13]. Quality/integrity of total and amplified mRNA (cRNA) was checked by spectrophotometer analysis, UV 260/280 ratio > 1.8, and/or agarose gel electrophoresis.///label_ch1: Cy5 / Cy3///label_protocol_ch1: All cRNA samples (1.5 g) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOK, Leiden, the Netherlands).///taxid_ch1: 9606///hyb_protocol: Protocol is available at http://microarrays.nki.nl/download/protocols/Hybridization_oligo_array_ULS_labeling_of_aRNA_2005.pdf///scan_protocol: Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) and expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK).///description: Channel 1 in raw data file ; Characteristics / Channel 2 in raw data file ; Characteristics///data_processing: raw data///platform_id: GPL7759///contact_name: Rudolf,Stephan Nicolaas,Fehrmann///contact_email: r.s.n.fehrmann@og.umcg.nl///contact_department: Gynecologic Oncology///contact_institute: University Medical Center Groningen///contact_address: P.O. Box 30.001///contact_city: Groningen///contact_state: Groningen///contact_zip.postal_code: 9700 RB///contact_country: Netherlands///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405752/GSM405752.xls.gz / ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM405nnn/GSM405892/GSM405892.xls.gz///data_row_count: 37632
1
(Other)
58
|
Value
An expression set
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.